• 1
    Singh J, Prentice AM, Diaz E, et al. Energy expenditure of Gambian women during peak agricultural activity measured by doubly-labeled water method. Br J Nutr. 1989;62: 31529.
  • 2
    Prentice AM, Black AE, Coward WA, et al. High levels of energy expenditure in obese women. Br Med J. 1986;292: 9837.
  • 3
    NHANES III. Third report on nutrition monitoring in the United States. 1988–1991;1.
  • 4
    Leaf A and Weber PC. A new era for science in nutrition. Am J Clin Nurr. 1987;45: 104853.
  • 5
    Lissner L, Levitsky DA, Strupp BJ, Kalkwarf HJ, Roe DA. Dietary fat and regulation of energy intake in human subjects. Am J Clin Nutr. 1987;46: 88692.
  • 6
    Tremblay A, Plourde G, Després JP, Bouchard C. Impact of dietary fat content and fat oxidation on energy intake in humans. Am J Clin Nutr. 1989;49: 799805.
  • 7
    Groop LC, Bonadonna RC, Simonson DC, Petrides AS, Shank M, DeFronzo RA. Effect of insulin on oxidative and nonoxidative pathways of free fatty acid metabolism in human obesity. Am J Physiol. 1992;263: E7984.
  • 8
    Astrup A, Buemann B, Western P, Toubro S, Raben A, Christensen NJ. Obesity as an adaptation to a high-fat diet: evidence from a cross-sectional study. Am J Clin Nutr. 1994; 59: 3505.
  • 9
    Schutz Y, Tremblay A, Weinsier RL, Nelson KM. Role of fat oxidation in the long-term stabilization of body weight in obese women. Am J Clin Nutr. 1992;55: 6704.
  • 10
    O'Dea K, Esler M, Leonard P, Stockigt JR, Nestel P. Noradrenaline turnover during under- and over-eating in normal weight subjects. Metabolism. 1982;319969.
  • 11
    Aronne LJ, Mackintosh R, Rosenbaum M, Leibel RL, Hirsch J. Autonomic nervous system activity in weight gain and weight loss. Am J Physiol. 1995;269: R2225.
  • 12
    Tremblay A, Nadeau A, Després J-P, Bouchard C. Hyperinsulinemia and regulation of energy balance. Am J Clin Nutr. 1995;61: 82730.
  • 13
    Considine RV, Shina MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese subjects. N Engl J Med. 1996;334: 2925.
  • 14
    Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease. Arteriosclerosis. 1990;10: 497511.
  • 15
    Doucet E, Imbeault P, Alméras N, Tremblay A. Physical activity and low-fat diet: Is it enough to maintain weight sta bility in the reduced-obese individual following weight loss by drug therapy and energy restriction Obes Res. 1999;7: 32333.
  • 16
    Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant-drugs. N Engl J Med. 1998;10: 7138.
  • 17
    Weissman NJ, Tighe JFJ, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients tak ing dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med. 1998;10: 72532.
  • 18
    Prud'homme D, Langlais M, Samson MP, Gallagher P, Turcotte J, Tremblay A, Després J. -P. Lack of major car diac valvular abnormalities in asymptomathic obese men and women following a 3-month fenfluramine or dexfenfluramine treatment. Int J Obes. 1999;23: S175.
  • 19
    The Canadian Nutrient File. Health and Welfare Canada; 1991.
  • 20
    Prud'Homme D, Bouchard C, Leblanc C, Landry F, Lortie G, Boulay MR. Reliability of assessments of ventilatory thresholds. J Sports Sci. 1984;2: 1324.
  • 21
    Lohman TG, Roche AF, Martorell R. Skinfold thicknesses and measurement technique. In: Lohman TG, Roche AF, Torell Mar R, eds. Anthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics Books; 1988: 5580.
  • 22
    Meneely EA, Kaltreider NL. Volume of the lung determined by helium dilution. J Clin Invest. 1949;28: 12939.
  • 23
    Kaltreider NL, Fray WW, Vanzile HH. Further studies of the total pulmonary capacity and its subdivisions in case of pulmonary fibrosis. J Ind Hyg Toxicol. 1937;19: 16376.
  • 24
    Siri WE. The gross composition of the body. Adv Biol Med Physiol. 1956;4: 23980.
  • 25
    Recommandations sur la nutrition. Santé et Bien-être (Canada): Centre d'édition du gouvernement du Canada; 1990: 224.
  • 26
    Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol. 1949;109: 19.
  • 27
    Richterich R, Dauwwalder H. Zur bestimmung der plasmaglukose-konzentration mit der hexokinase-glucose-6-phosphatdeshydrogenase-methode. Schweiz Med Wochenschr. 1971; 101: 6158.
  • 28
    Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrind Metab. 1971;37: 7328.
  • 29
    Moorjani S, Gagné C, Lupien PJ, Brun D. Plasma triglycerides related decrease in high density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemia. Metabolism. 1986;35: 3116.
  • 30
    Gidez LI, Miller GJ, Burstein M, Slage S, Eder HH. Sepa ration and quantitation of subclasses of human high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982;23: 120613.
  • 31
    Avogaro P, Bon Bittolo G, Cazzolato G, Quinci GB. Are apolipoproteins better discriminators than lipids for athero sclerosis Lancet. 1979; 1: 9013.
  • 32
    Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Ter Fos GA. Treatment of obesity by very low calorie diet, behav ior therapy, and their combination: a five year perspective. Int J Obes. 1989; 13: 3946.
  • 33
    Foster GD, Wadden TA, Peterson FJ, Letizia KA, Bartlett SJ, Conill AM. A controlled comparison of three very-low-calorie diets: effects on weight, body composition, and symp toms. Am J Clin Nutr. 1992;55: 8117.
  • 34
    Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fen fluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992;51: 58694.
  • 35
    Guy-Grand B. Clinical studies with d-fenfluramine. Am J Clin Nutr. 1992; 55: 173s6s.
  • 36
    James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes. 1997;21: S2430.
  • 37
    Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes. 1998;22: 328.
  • 38
    Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res. 1998;6: 11521.
  • 39
    Siggaard R, Raben A, Astrup A. Weight loss during 12 week's ad libitum carbohydrate-rich diet in overweight and normal-weight subjects at a Danish work site. Obes Res. 1996; 4: 34756.
  • 40
    Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes. 1992;16: 397415.
  • 41
    Andersen RE, Wadden TA, Bartlett SJ, Vogt RA, Weinstock RS. Relation of weight loss to changes in serum lipids and lipoproteins in obese women. Am J Clin Nutr. 1995;62: 3507.
  • 42
    Tremblay A, Després J-P, Maheux J, et al. Normalization of the metabolic profile in obese women by exercise and a low fat diet. Med Sci Sports Exerc. 1991;23: 132631.
  • 43
    Tremblay A, Sauve L, Despres JP, Nadeau A, Theriault G, Bouchard C. Metabolic characteristics of postobese individu als. Int J Obes. 1989; 13: 35766.
  • 44
    Campfield LA, Smith FJ. Functional coupling between tran sient declines in blood glucose and feeding behavior: temporal relationships. Brain Res Bull. 1986; 17: 42733.
  • 45
    Harris MI, Hadden WC, Knowler WC, Bennett PH. Preva lence of diabetes and impaired glucose tolerance and plasma glucose levels in U. S. population aged 20–74 yr. Diabetes. 1987;36: 52334.
  • 46
    Couillard C, Lemieux S, Moorjani S, et al. Associations between 12 year changes in body fatness and lipoprotein-lipid levels in men and women of the Quebec Family Study. Int J Obes Relat Metab Disord. 1996;20: 10818.
  • 47
    Abbott RD, Garrison RJ, Wilson PW, et al. Joint distribu tion of lipoprotein cholesterol classes. The Framingham study. Arteriosclerosis. 1983;3: 26072.